Transcriptome analysis of Enzalutamide-sensitive and -resistant CWR-R1, C4-2B, and VCaP cells

Enzalutamide (ENZ) is an inhibitor of the androgen receptor (AR) widely used in managing castration-resistant prostate cancer (CRPC). However, ENZ is not curative due to the resistance CRPC inevitably develops. We hypothesize that there are commonly necessary elements of ENZ resistance in cells with different genetic mutations and treatment history. This study aims to identify differentially expressed genes in Enzalutamide-sensitive (ENZS) and ENZ-resistant (ENZR) C4-2B, CWR-R1, VCaP human prostate cell lines. We have identified 114 commonly upregulated genes in all three ENZR celll lines, which will be subjected to further investigation for their roles in ENZ resistance. Overall design: Total RNA was isolated from ENZS and ENZR cells of the three lineages and sent to Novogene for library preparation and paired end sequencing. Differential expression analysis was performed by TAC genomics.